Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS
This article was originally published in Scrip
Sanofi company Genzyme has entered a collaboration with Cambridge, Massachusetts-based Voyager Therapeutics focused on the discovery of gene therapies for severe CNS disorders.
You may also be interested in...
Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
The gene therapy developer described Sanofi's decision to give up ex-US rights to VY-AADC01 as good news, but its stock price fell anyway. Voyager maintains that it wasn't necessarily counting on its partner to opt in, so it has enough funding without Sanofi to conduct a Phase II/III study.